Incorporating Checkpoint Inhibitor Therapy Into the Management of Head and Neck Squamous Cell Carcinoma

Emerging clinical data and expert guidance on checkpoint inhibitors and other treatment options for head and neck squamous cell carcinoma.
Barbara Burtness, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.99 MB
Released: September 3, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Merck & Co., Inc.

Related Content

In slides from Clinical Care Options (CCO), experts provide perspectives on updates in biomarker testing and targeted therapy across GI cancers

John L. Marshall, MD
Program Director
Christopher H. Lieu, MD Manish A. Shah, MD
Released: January 19, 2023

Downloadable slideset from a live meeting series for endocrinologists featuring best practices for biomarker testing and the latest evidence on targeted therapies for advanced thyroid cancer, from Clinical Care Options (CCO)

person default Maria E Cabanillas, MD person default Lori J. Wirth, MD Released: January 4, 2023

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer

person default Saad A. Khan, MD Sandip P. Patel, MD Released: November 17, 2022

Downloadable resource on the role of RET and NTRK aberrations in lung and thyroid cancer, including guidance on testing and review of the clinical data on RET and NTRK inhibitor therapy for these diseases, from Clinical Care Options (CCO)

Released: November 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings